Lexicon Pharmaceuticals, Inc. LXRX
1.80
(0.06)
(3.23%)
as of 25 Sep
- Market cap
- $854.3M
- P/E
- 0.0×
Follow LXRX
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (40.21%) | (16.01%) | (39.72%) | (45.92%) |
+8 more TTM periods Free account |
|
| (25.70%) | (9.21%) | (20.83%) | (26.02%) | ||
ROIC |
(96.36%) | (18.49%) | (46.81%) | (68.83%) | |
Return on Tangible Assets |
(33.30%) | (14.67%) | (60.73%) | (66.72%) | |
Average Days of Receivables |
14.46 | 61.73 | 17.47 | 12.02 | |
Free Cash Flow per Share |
(0.15) | (0.10) | (0.19) | (0.20) | |
Free Cash Flow |
(64.99) | (38.80) | (67.85) | (72.11) | |
Piotroski F-Score |
3.00 | 5.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(15.60%) | (9.17%) | (26.32%) | (24.64%) | |
Accounts Receivable Turnover |
21.68 | 2.35 | 17.01 | 27.10 | |
Accounts Payable Turnover |
0.09 | 0.05 | 0.03 | 0.05 | |
Inventory Turnover |
0.52 | 1.48 | 1.07 | 1.06 | |
Average Days of Payables |
2,388.81 | 3,106.65 | 4,106.92 | 3,291.94 | |
Days of Inventory on Hand |
1,219.39 | 286.19 | 374.32 | 136.98 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
145.34% | 84.11% | 122.73% | 107.94% | |
Selling, General and Administrative Expense of Revenue |
85.23% | 50.18% | 74.93% | 85.82% | |
Share Based Compensation of Revenue |
30.61% | 18.02% | 25.13% | 15.83% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.06 | 1.49 | 1.35 | 1.05 | |
Depreciation/Fixed assets |
1.57 | 1.45 | 1.25 | 1.13 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.09 | 0.17 | 0.14 | 0.20 | |
Operating CF per Share |
(0.15) | (0.10) | (0.19) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(147.38%) | (37.46%) | (101.08%) | (96.77%) |
Columns are period end dates